Enterprise Value

148.7M

Cash

65.19M

Avg Qtr Burn

-4.546M

Short % of Float

12.99%

Insider Ownership

11.04%

Institutional Own.

33.76%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COSELA™ Trilaciclib (G1T28) (CDK4/6 inhibitor) Details
Cancer, Solid tumor/s, Small cell lung cancer

Approved

Quarterly sales

Trilaciclib (Cosela) (CDK4/6 inhibitor) Details
Breast cancer, Cancer, Triple-negative breast cancer

Phase 3

Update

Phase 2

Update

Trilaciclib (Cosela) + Trodelvy® (sacituzumab govitecan-hziy) (ADC) Details
Solid tumor/s, Cancer, Metastatic breast cancer, Triple-negative breast cancer , Breast cancer

Phase 2

Update

Phase 2

Update

Failed

Discontinued

Trilaciclib (Cosela) (CDK4/6 inhibitor) Details
Cancer, Non-small cell lung carcinoma, Solid tumor/s

Failed

Discontinued

Failed

Discontinued